ATE435033T1 - G-csf konjugate - Google Patents

G-csf konjugate

Info

Publication number
ATE435033T1
ATE435033T1 AT01900105T AT01900105T ATE435033T1 AT E435033 T1 ATE435033 T1 AT E435033T1 AT 01900105 T AT01900105 T AT 01900105T AT 01900105 T AT01900105 T AT 01900105T AT E435033 T1 ATE435033 T1 AT E435033T1
Authority
AT
Austria
Prior art keywords
csf conjugates
csf
conjugates
Prior art date
Application number
AT01900105T
Other languages
English (en)
Inventor
Torben Lauesgaard Nissen
Kim Vilbour Andersen
Christian Karsten Hansen
Jan Moller Mikkelsen
Hans Thalsgaard Schambye
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Application granted granted Critical
Publication of ATE435033T1 publication Critical patent/ATE435033T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01900105T 2000-01-10 2001-01-09 G-csf konjugate ATE435033T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000024 2000-01-10
DKPA200000341 2000-03-02
DKPA200000943 2000-06-16
PCT/DK2001/000011 WO2001051510A2 (en) 2000-01-10 2001-01-09 G-csf conjugates

Publications (1)

Publication Number Publication Date
ATE435033T1 true ATE435033T1 (de) 2009-07-15

Family

ID=27222334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900105T ATE435033T1 (de) 2000-01-10 2001-01-09 G-csf konjugate

Country Status (20)

Country Link
EP (2) EP2133098A1 (de)
JP (1) JP2003519478A (de)
KR (1) KR100773323B1 (de)
CN (1) CN1188172C (de)
AR (1) AR027509A1 (de)
AT (1) ATE435033T1 (de)
AU (2) AU782580B2 (de)
BR (1) BR0107561A (de)
CA (1) CA2395713C (de)
CZ (1) CZ20022727A3 (de)
DE (1) DE60139110D1 (de)
DK (1) DK1250154T3 (de)
ES (1) ES2327606T3 (de)
HU (1) HUP0203751A3 (de)
IL (2) IL150153A0 (de)
MX (1) MXPA02006795A (de)
NO (1) NO20023315L (de)
NZ (1) NZ520261A (de)
SK (1) SK11672002A3 (de)
WO (1) WO2001051510A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022727A3 (cs) * 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
GB0022877D0 (en) * 2000-09-18 2000-11-01 Isis Innovation Analogues
IL159524A0 (en) 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
CN105131104B (zh) * 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
WO2003078461A1 (en) * 2002-03-20 2003-09-25 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
US7344858B2 (en) * 2002-08-31 2008-03-18 Cj Corp Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
JPWO2004100972A1 (ja) * 2003-05-16 2006-07-13 協和醗酵工業株式会社 組織破壊を伴う疾患の予防及び/または治療剤
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2560657T3 (es) * 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
PL2586456T3 (pl) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
EP1817047B1 (de) 2004-11-05 2012-02-08 Northwestern University Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−2組成物
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
EP1891231A4 (de) 2005-05-25 2011-06-22 Novo Nordisk As Glykopegylierter faktor ix
US7381805B2 (en) * 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス ポリペプチドコンジュゲートの精製方法
BRPI0809670A8 (pt) 2007-04-03 2018-12-18 Biogenerix Ag métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
WO2008147534A1 (en) * 2007-05-22 2008-12-04 Maxygen Holdings Ltd. Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
NZ583276A (en) 2007-08-27 2012-06-29 Biogenerix Ag Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009103199A1 (zh) 2008-02-18 2009-08-27 江苏恒瑞医药股份有限公司 水溶性聚合物修饰的g-csf偶联物
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
WO2010001414A1 (en) * 2008-07-03 2010-01-07 Lupin Limited Expression of heterologous proteins in bacterial system using a gm-csf fusion tag
CA2738116C (en) 2008-10-02 2016-10-18 Octapharma Ag Improved processing of recombinant human g-csf
US20150166629A1 (en) * 2012-04-17 2015-06-18 Aarhus Universitet SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT
KR101623906B1 (ko) 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
CN107916257B (zh) * 2018-01-09 2020-07-28 华南理工大学 T1脂肪酶突变体和应用
MX2022003886A (es) * 2019-10-08 2022-07-12 Zymeworks Inc Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen.

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4470461A (en) 1982-09-30 1984-09-11 Phillips Petroleum Company Organic nitro compounds as cosurfactants in enhanced oil recovery processes
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
ATE93541T1 (de) 1985-07-03 1993-09-15 Genencor Int Hybride polypeptide und verfahren zu deren herstellung.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
WO1987002670A1 (en) 1985-10-25 1987-05-07 Mackay Vivian L Method of using bar1 for secreting foreign proteins
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
US5714581A (en) 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (es) 1989-04-19 2006-03-01 Enzon, Inc. Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
EP0400472B1 (de) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine.
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
ATE203415T1 (de) 1994-02-08 2001-08-15 Amgen Inc Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
EP1462096B1 (de) 1994-03-07 2008-12-10 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
AU2826495A (en) 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
EP1559776A3 (de) 1994-06-30 2006-01-11 Novozymes Biotech, Inc. Nicht-toxisches, nicht-toxigenes, nicht-pathogenes Fusarium Expressionssystem und darin zu verwendende Promotoren und Terminatoren
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1997007205A1 (en) 1995-08-11 1997-02-27 Novo Nordisk A/S Method for preparing polypeptide variants
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
SI0964702T1 (sl) 1996-08-02 2007-02-28 Ortho Mcneil Pharm Inc Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
EP0954589A1 (de) 1997-01-24 1999-11-10 Novo Nordisk A/S Sythetische signalpeptid-sequenzen.
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
EP0921131B1 (de) 1997-06-06 2010-05-26 Kyowa Hakko Kirin Co., Ltd. Chemisch modifizierte polypeptide
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
AU762621B2 (en) 1998-04-28 2003-07-03 Merck Serono Sa Polyol-IFN-beta conjugates
ATE465459T1 (de) 1999-01-19 2010-05-15 Maxygen Inc Durch oligonukleotide-vermittelte nukleinsäuren- rekombination
CZ20022727A3 (cs) * 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek

Also Published As

Publication number Publication date
CA2395713C (en) 2012-04-10
CN1188172C (zh) 2005-02-09
KR100773323B1 (ko) 2007-11-05
HUP0203751A3 (en) 2005-01-28
WO2001051510A2 (en) 2001-07-19
IL150153A (en) 2009-12-24
NO20023315D0 (no) 2002-07-09
AU2353301A (en) 2001-07-24
HUP0203751A2 (hu) 2003-07-28
IL150153A0 (en) 2002-12-01
MXPA02006795A (es) 2005-04-19
EP2133098A1 (de) 2009-12-16
DE60139110D1 (de) 2009-08-13
EP1250154B1 (de) 2009-07-01
HK1051964A1 (en) 2003-08-29
NO20023315L (no) 2002-09-05
CN1404401A (zh) 2003-03-19
AU2005222524A1 (en) 2005-11-10
WO2001051510A3 (en) 2002-03-21
NZ520261A (en) 2003-10-31
AU2005222524B2 (en) 2008-12-11
JP2003519478A (ja) 2003-06-24
AU782580B2 (en) 2005-08-11
AR027509A1 (es) 2003-04-02
KR20020079778A (ko) 2002-10-19
EP1250154A2 (de) 2002-10-23
SK11672002A3 (sk) 2002-12-03
DK1250154T3 (da) 2009-08-17
ES2327606T3 (es) 2009-11-02
CA2395713A1 (en) 2001-07-19
BR0107561A (pt) 2002-11-19
CZ20022727A3 (cs) 2002-11-13

Similar Documents

Publication Publication Date Title
DE60139110D1 (de) G-csf konjugate
DE10195164T1 (de) Hochgeschwindigkeitsverbindung
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
DZ3409A1 (fr) Association therapeuthique
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DK1303521T3 (da) Tetrahydro-heterocycloazepinyl-pyrimidinderivater
DE50114386D1 (de) Ng
EE05197B1 (et) Linesoliid - kristallivorm II
ATE262530T1 (de) Indolochinazolinone
MA26998A1 (fr) Conjugues peg de hgt-nk4
ATE298751T1 (de) 7-oxopyridoryrimidine
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE10192638T1 (de) Bohrstangenladevorrichtung
ATE509008T1 (de) Sulfonylguanidine
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
AR027931A1 (es) Antitranspirantes
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE10052925B4 (de) Schaukelbett
ATE476423T1 (de) Benzoylpyridazine
DE10195909T1 (de) Viehfüttervorrichtung
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties